Prospective Study
Copyright ©The Author(s) 2017.
World J Gastrointest Pathophysiol. Aug 15, 2017; 8(3): 133-141
Published online Aug 15, 2017. doi: 10.4291/wjgp.v8.i3.133
Table 1 Baseline characteristics of patients in treatment (n = 51) and control group (n = 50) n (%)
ParametersControl groups (n = 50)Treatment groups (n = 51)P-value
Age (yr) (mean ± SD)43.28 ± 12.5346.21 ± 14.93> 0.05
Sex (M:F)37:1340:11
Mean (CI) serum bilirubin (mg/dL)8.95 (6.62-11.29)6.89 (5.15-8.64)> 0.05
Mean (CI) PT - INR1.50 (1.41-1.59)1.43 (1.37-1.48)> 0.05
ALT (IU/L)92 (61-119)84 (62-106)> 0.05
AST (IU/L)157 (98-215)127 (106-147)> 0.05
Mean (CI) serum albumin (g/dL)2.41 (2.32-2.50)2.38 (2.28-2.49)> 0.05
Mean (CI) serum creatinine1.11 (1.04-1.17)1.18 (1.13-1.24)> 0.05
Mean (CI) blood TLC (mm3/μL)10902 (9481-12322)8407 (7238-9576)< 0.05
Mean (CI) Ascitic fluid TLC (mm3/μL)233.84 (187.41-280.27)237.92 (193.48-282.32)> 0.05
Ascites50 (100)51 (100)> 0.05
Jaundice40 (80)41 (80.4)> 0.05
Encephalopathy21 (42)27 (52.94)> 0.05
Fever19 (38)10 (20)< 0.05
Mean (CI) CTP score10.92 (10.64-11.20)11.17 (10.83-11.52)> 0.05
Mean (CI) MELD score19.02 (17.91-20.12)18.62 (17.70-19.54)> 0.05
Etiology of CLD (%)Ethanol (48), HBV (20), Cryptogenic (14), HCV (8), Ethanol + HBV (6), NASH (2), Wilson’s disease (2)Ethanol (38), HBV (24), Cryptogenic (20), Ethanol + HBV (10), HCV (8), NASH (4)